Allarta Life Science, the Hamilton-based regenerative medicine company using novel hydrogels to enable cell-based therapies for type 1 diabetes (T1D), recently announced it has received an award from JDRF, the leading global T1D research and advocacy organization, that could amount to US$800,000 upon completion of research and development milestones.
The award will directly fund Allarta’s ongoing work to increase durability and avoid the need for systemic immune suppression in current islet and beta cell transplantations to cure T1D.
Allarta is an OBIO® member and an alumnus of our CAAP® and workforce development programs.